Please use this identifier to cite or link to this item:
|Title:||Retinal vascular changes following intravitreal ranibizumab injections for neovascular AMD over a 1-year period||Authors:||Wickremasinghe, S.S.
|Issue Date:||Jul-2012||Citation:||Wickremasinghe, S.S., Xie, J., Guymer, R.H., Wong, T.Y., Kawasaki, R., Qureshi, S. (2012-07). Retinal vascular changes following intravitreal ranibizumab injections for neovascular AMD over a 1-year period. Eye (Basingstoke) 26 (7) : 958-966. ScholarBank@NUS Repository. https://doi.org/10.1038/eye.2012.72||Abstract:||Purpose: To assess retinal vascular calibre changes in eyes with neovascular age-related macular degeneration (AMD), treated with intravitreal anti-vascular endothelial growth factor agents, over a 1-year period and compare any such changes to untreated fellow eyes. Methods: Treatment naïve patients with neovascular AMD received three consecutive intravitreal injections of ranibizumab, followed by a pro re nata dosing regimen up to 1 year, with the aim of maintaining a 'fluid-free' macula. Retinal arteriolar and venular calibre was measured from digital fundus photographs at baseline and at three monthly intervals to 1 year, and summarised as central retinal artery equivalent (CRAE) and central retinal venular equivalent (CRVE), respectively. Results: A total of 53 injected eyes and 41 fellow, non-injected eyes were analysed. At baseline, there were no differences in retinal vascular calibre between injected and non-injected eyes (mean CRAE (SD) 144.93 (14.07) vs 145.74 (13.10) μm, P=0.80 and mean CRVE (SD) 216.23 (25.93) vs 219.91 (22.82) μm, P=0.53). Over a 12-month period, retinal venular calibre dilatation occurred in injected eyes (mean CRVE change +5.71 (14.71) μm, P=0.007), with no change in retinal arterioles, +0.69 (14.71) μm, P=0.68. In non-injected eyes, arteriolar narrowing occurred as a whole, mean CRAE change -4.20 (7.00) μm, P=0.001, over 12 months, with a trend for narrowing in venules, -2.16 (11.56) μm, P=0.28. In injected eyes, after controlling for covariates, the changes in CRVE over 12 months mirrored improvements in macular thickness, -0.06 (-0.005, -0.11) μm, P=0.04, and visual acuity, +9.66 (-0.30, +19.32) μm, P=0.06. Conclusion: Intravitreal ranibizumab significantly dilated retinal venules after a 1-year period. © 2012 Macmillan Publishers Limited All rights reserved.||Source Title:||Eye (Basingstoke)||URI:||http://scholarbank.nus.edu.sg/handle/10635/109608||ISSN:||0950222X||DOI:||10.1038/eye.2012.72|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Mar 29, 2023
WEB OF SCIENCETM
checked on Mar 29, 2023
checked on Mar 30, 2023
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.